Cell Genesys, Inc. (NASDAQ: CEGE)

Cell Genesys, Inc. (NASDAQ: CEGE) has their focus on developing and commercializing novel biological therapies for cancer patients. GVAX® cancer imunotherapy, the company’s lead product platform, holds the potential to treat several types of cancer. Cell Genesys also holds an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. For further information, visit the Company’s web site at www.cellgenesys.com.